South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named ...

Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...

US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab ...

Mountainfield Venture Partners and Keymed Biosciences launch Timberlyne Therapeutics with $180 million in series A funding.

USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million ...

The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% ...

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

Numab Therapeutics raises $55 million to advance its multi-specific antibody pipeline targeting inflammation and oncology, ...

The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering ...

USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for ...